Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...

Eli Lilly is cutting introductory Zepbound prices again, with the lowest dose now $299 monthly for cash-pay customers, a $50 ...

This is the second time Eli Lilly has cut prices of Zepbound on LillyDirect. The pharmaceutical company said it is making the ...

Eli Lilly said it has lowered the price of single-dose vials of its popular obesity drug Zepbound to make the treatment more ...

Eli Lilly is cutting what self-paying patients shell out for its blockbuster obesity drug Zepbound when they buy single-dose ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...

Eli Lilly & Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up with rival Novo Nordisk A/S.

Eli Lilly slashes Zepbound to £227 ($299) monthly for US cash payers, but just £31 ($41) in India – though £241 ($319) in Japan.

The decision is the latest in a series of moves to make its GLP-1 blockbuster more widely available and affordable.

Lilly lowers the price of its obesity drug Zepbound to make it more affordable for U.S. patients. Surging demand propels ...